412 related articles for article (PubMed ID: 28057932)
1. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.
Lesterhuis WJ; Bosco A; Millward MJ; Small M; Nowak AK; Lake RA
Nat Rev Drug Discov; 2017 Apr; 16(4):264-272. PubMed ID: 28057932
[TBL] [Abstract][Full Text] [Related]
2. Prospect for immune checkpoint blockade: dynamic and comprehensive monitorings pave the way.
Wang W; Liu J; He Y; McLeod HL
Pharmacogenomics; 2017 Aug; 18(13):1299-1304. PubMed ID: 28745931
[TBL] [Abstract][Full Text] [Related]
3. Antibody-based immunotherapy of solid cancers: progress and possibilities.
Nicodemus CF
Immunotherapy; 2015; 7(8):923-39. PubMed ID: 26314410
[TBL] [Abstract][Full Text] [Related]
4. Strategies for Predicting Response to Checkpoint Inhibitors.
Zappasodi R; Wolchok JD; Merghoub T
Curr Hematol Malig Rep; 2018 Oct; 13(5):383-395. PubMed ID: 30159703
[TBL] [Abstract][Full Text] [Related]
5. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
Koster BD; de Gruijl TD; van den Eertwegh AJ
Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
7. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic use of anti-CTLA-4 antibodies.
Blank CU; Enk A
Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy.
Lee L; Gupta M; Sahasranaman S
J Clin Pharmacol; 2016 Feb; 56(2):157-69. PubMed ID: 26183909
[TBL] [Abstract][Full Text] [Related]
10. Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy.
Proia DA; Kaufmann GF
Cancer Immunol Res; 2015 Jun; 3(6):583-9. PubMed ID: 25948551
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
Adachi K; Tamada K
Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
[TBL] [Abstract][Full Text] [Related]
12. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.
Hegde PS; Karanikas V; Evers S
Clin Cancer Res; 2016 Apr; 22(8):1865-74. PubMed ID: 27084740
[TBL] [Abstract][Full Text] [Related]
13. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations.
Baksh K; Weber J
Semin Oncol; 2015 Jun; 42(3):363-77. PubMed ID: 25965355
[TBL] [Abstract][Full Text] [Related]
15. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
Lin F; Li Z; Hua Y; Lim YP
Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Blockade in Cancer Therapy.
Postow MA; Callahan MK; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
[TBL] [Abstract][Full Text] [Related]
17. The sentinel within: exploiting the immune system for cancer biomarkers.
Anderson KS; LaBaer J
J Proteome Res; 2005; 4(4):1123-33. PubMed ID: 16083262
[TBL] [Abstract][Full Text] [Related]
18. [Genome-Based Biomarkers of Immune Checkpoint Blockade Therapy].
Adachi K; Tamada K
Gan To Kagaku Ryoho; 2016 Feb; 43(2):143-50. PubMed ID: 27067677
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
Pico de Coaña Y; Choudhury A; Kiessling R
Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
[TBL] [Abstract][Full Text] [Related]
20. The potential of DNA modifications as biomarkers and therapeutic targets in oncology.
Jankowska AM; Millward CL; Caldwell CW
Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
